31
Participants
Start Date
September 29, 2017
Primary Completion Date
April 5, 2018
Study Completion Date
April 5, 2018
Treatment A - AZD1775 administered under fasted conditions
Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
Treatment B - AZD1775 administered under fed conditions.
"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.~Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.~The drug class of AZD1775 is Wee-1 kinase inhibitor."
Research Site, Bordeaux
Research Site, Saint-Herblain
Research Site, Amsterdam
Research Site, Amsterdam
Research Site, Maastricht
Research Site, Glasgow
Research Site, Manchester
Lead Sponsor
Quintiles, Inc.
INDUSTRY
AstraZeneca
INDUSTRY